Documents

Q2 delivered sales growth and strong brand momentum, with full-year guidance reaffirmed.

Priority brands delivered robust growth, supporting a positive long-term outlook despite generic headwinds.

Large patient populations across major diseases highlight ongoing unmet needs in advanced therapies.

Shareholders approved all proposals amid strong results, dividend growth, and strategic focus.

Strong pipeline, commercial execution, and innovation drive long-term growth and value.

Achieved 8% sales growth, 40.1% core margin, and record free cash flow, with strong brand momentum.

Advancing Global Health, access, and sustainability with innovation, partnerships, and measurable impact.

Disciplined M&A, robust cash flow, and AI-driven efficiency underpin long-term growth.

Upgraded growth guidance and a catalyst-rich pipeline drive strong long-term outlook.

RHAPSIDO and ianalumab drive immunology growth, with strong launches and broad expansion plans.

Q3 saw robust sales and income growth, with 2025 guidance reaffirmed.